Skip to main content
Funded Studies

Anthony Schapira, MD, DSc, FRCP, FMedSci

Chair of the Department of Clinical and Movement Neurosciences, and Professor of Neurology at UCL Queen Square Institute of Neurology

Location: London United Kingdom

Anthony Schapira was appointed chairman of clinical neurosciences at the UCL Queen Square Institute of Neurology and professor of neurology at the National Hospital for Neurology and Neurosurgery and the Royal Free Hospital, London, UK. He is currently head of the department of clinical and movement neurosciences at UCL Queen Square Institute of Neurology. Professor Schapira runs a movement disorders clinic in addition to a basic science laboratory. His research interests include the molecular and clinical aspects of neurodegenerative diseases, with special emphasis on Parkinson’s disease (PD) and other movement disorders. His laboratory focuses of on understanding the biochemical consequences of glucocerebrosidase mutations and their relationship to alpha-synuclein pathology in PD, and he leads the clinical cohort analysis of GBA carrier recruitment (https://www.rapsodistudy.com). Professor Schapira has produced over 450 peer-reviewed publications and has edited more than 15 books on various aspects of neurology, including the textbook Neurology and Clinical Neuroscience. 


Associated Grants

  • Use of Novel Intestinal Imaging for Early Identification of Parkinson’s Disease and Assessment of Response to Therapies that Reduce Alpha-synuclein Accumulation

    2022


  • The Genome-Microbiome Axis in the Cause of Parkinson Disease: Mechanistic Insights and Therapeutic Implications from Experimental Models and a Genetically Stratified Patient Population

    2020


  • Investigation of the Contribution of Copy Number Alterations in Parkinson’s Disease Genes to Pathogenesis

    2013


  • Development of an HTS Assay to Break the Alpha-Synuclein-Glucocerebrosidase Feedback Loop

    2012


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.